Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
